Abpro Holdings Receives FDA IND Clearance for Lead Oncology Candidate ABP-102 / CT-P72

summarizeSummary

Abpro Holdings announced FDA Investigational New Drug (IND) clearance for its lead multispecific antibody oncology program, ABP-102 / CT-P72, enabling the initiation of a Phase 1 clinical trial.

check_boxKey Events

• FDA IND Clearance for Lead Oncology Program

  The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, Abpro's lead multispecific antibody oncology program, co-developed with Celltrion, Inc.

• Initiation of Phase 1 Clinical Trial

  This clearance enables the initiation of a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 / CT-P72 in patients with HER2-positive solid tumors, anticipated in the first half of 2026.

• Strategic Co-Development with Celltrion

  The Phase 1 clinical study will be led by co-development partner Celltrion, Inc., underscoring the ongoing joint strategic collaboration for the program's robust progression.

• Differentiated Therapeutic Design

  ABP-102 / CT-P72 is a multispecific HER2 x CD3 T-cell engager engineered for enhanced tumor selectivity and optimized CD3 binding, aiming to minimize damage to healthy tissue and reduce the risk of cytokine release syndrome.

auto_awesomeAnalysis

The FDA Investigational New Drug (IND) clearance for ABP-102 / CT-P72 is a significant milestone for Abpro Holdings, as it transitions their lead multispecific antibody oncology program from preclinical to clinical development. For a biotechnology company, advancing a drug candidate into Phase 1 trials is a critical de-risking event that validates the preclinical work and opens the path for potential future commercialization. The co-development with Celltrion, Inc. further strengthens the program's credibility and resource backing. This development could attract increased investor attention, given the high unmet medical need in HER2-positive solid tumors and the differentiated design of ABP-102 / CT-P72 aimed at improving safety and efficacy.